Literature DB >> 10648645

Differential regulation of prostaglandin F(2alpha) receptor isoforms by protein kinase C.

H Fujino1, D Srinivasan, K L Pierce, J W Regan.   

Abstract

Prostaglandin F(2alpha) receptors (FP) are G protein-coupled receptors that bind prostaglandin F(2alpha) (PGF(2alpha)), resulting in the activation of an inositol phosphate (IP) second messenger pathway. Alternative mRNA splicing generates two FP receptor isoforms. These isoforms, designated FP(A) and FP(B), are otherwise identical except for their carboxyl termini. FP(B) is essentially a truncated version of FP(A) that lacks the 46 carboxyl-terminal amino acids, including four putative protein kinase C (PKC) phosphorylation sites. Until now, functional differences between these FP receptor isoforms have not been identified. We now report that pretreatment with the PKC inhibitor bisindolylmaleimide I enhanced PGF(2alpha)-stimulated IP accumulation in transfected cells stably expressing the FP(A) isoform but not in cells stably expressing the FP(B) isoform. Whole-cell phosphorylation experiments showed a strong agonist-dependent phosphorylation of the FP(A) isoform but little or no phosphorylation of the FP(B). Pretreatment of cells with bisindolylmaleimide I decreased PGF(2alpha)-stimulated phosphorylation of the FP(A) isoform consistent with a PKC-dependent phosphorylation. In vitro phosphorylation of an FP(A) carboxyl-terminal fusion protein by recombinant PKCalpha showed that the carboxyl terminus of the FP(A) is a substrate for PKC. These results suggest that PKC-dependent phosphorylation is responsible for differential regulation of second messenger signaling by FP prostanoid receptor isoforms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648645

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression.

Authors:  Raymond L Konger; Glynis A Scott; Yvonne Landt; Jack H Ladenson; Alice P Pentland
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway.

Authors:  Ruyue Ji; Chih-Ling Chou; Wei Xu; Xiao-Bo Chen; David F Woodward; John W Regan
Journal:  Mol Pharmacol       Date:  2010-03-24       Impact factor: 4.436

3.  Cyclic AMP-mediated chloride secretion is induced by prostaglandin F2alpha in human isolated colon.

Authors:  D Collins; A M Hogan; M M Skelly; A W Baird; D C Winter
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

4.  Effects of prostaglandin F2α on small intestinal interstitial cells of Cajal.

Authors:  Chan Guk Park; Young Dae Kim; Man Yoo Kim; Jae Woong Koh; Jae Yeoul Jun; Cheol Ho Yeum; Insuk So; Seok Choi
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

5.  Role of the ERC motif in the proximal part of the second intracellular loop and the C-terminal domain of the human prostaglandin F2alpha receptor (hFP-R) in G-protein coupling control.

Authors:  Andrea Pathe-Neuschäfer-Rube; Frank Neuschäfer-Rube; Gerhard P Püschel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

6.  Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells.

Authors:  Eugénie Goupil; Dany Fillion; Stéphanie Clément; Xiaoyan Luo; Dominic Devost; Rory Sleno; Darlaine Pétrin; H Uri Saragovi; Éric Thorin; Stéphane A Laporte; Terence E Hébert
Journal:  J Biol Chem       Date:  2014-12-15       Impact factor: 5.157

7.  Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes.

Authors:  Y Liang; D F Woodward; V M Guzman; C Li; D F Scott; J W Wang; L A Wheeler; M E Garst; K Landsverk; G Sachs; A H-P Krauss; C Cornell; J Martos; S Pettit; H Fliri
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.